<DOC>
	<DOCNO>NCT00053872</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving radiation therapy different way combination chemotherapy may kill remain tumor cell follow surgery . It yet know radiation therapy regimen combine combination chemotherapy effective treating medulloblastoma . PURPOSE : Randomized phase III trial compare different radiation therapy regimens plus combination chemotherapy treat child undergone surgery medulloblastoma .</brief_summary>
	<brief_title>Radiation Therapy Plus Combination Chemotherapy Treating Children With Medulloblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare event-free survival rate pediatric patient standard-risk medulloblastoma treat conventional v hyperfractionated radiotherapy vincristine follow maintenance cisplatin , lomustine , vincristine . - Compare overall survival patient treat regimen . - Compare pattern relapse , especially local relapse ( tumor bed posterior fossa outside tumor bed ) , patient treat regimen . - Determine toxicity surgery whether identifiable factor correlate toxicity patient . - Determine impact surgical complication commencement adjuvant therapy event-free survival patient . - Compare late sequela , term health status , endocrine deficiency , hear loss , patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord country . Patients randomize 1 2 treatment arm . - Arm I : Within 28-40 day surgical resection , patient undergo conventional fractionated radiotherapy daily , 5 day week , 6-7 week . Patients also receive vincristine IV weekly 8 week . - Arm II : Beginning arm I , patient undergo hyperfractionated radiotherapy twice daily , 5 day week , 6-7 week . Patients also receive vincristine arm I . - Maintenance chemotherapy : Six week completion radiotherapy , patient receive cisplatin IV 6 hour oral lomustine day 1 vincristine IV day 1 , 8 , 15 . Treatment repeat every 6 week 8 course . Patients follow least every 6 month 3 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 316 patient ( 158 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm medulloblastoma , include follow variant : Classic Nodular/desmoplastic Large cell Melanotic Medullomyoblastoma Prior total subtotal surgical removal tumor within past 2840 day No 1.5 cm^2 residual tumor early postoperative MRI CT scan No brainstem supratentorial primitive neuroectodermal tumor No atypical teratoid rhabdoid tumor No know predisposition medulloblastoma ( e.g. , Gorlin 's syndrome ) No CNS metastasis ( supratentorial , arachnoid posterior fossa , craniospinal axis ) MRI No clinical evidence metastasis outside CNS No tumor cell lumbar cerebrospinal fluid cytospin PATIENT CHARACTERISTICS : Age 3 21 Performance status Not specify Life expectancy Not specify Hematopoietic Hematological function less CTC grade 2 Hepatic Liver function less CTC grade 2 Renal Renal function less CTC grade 2 Other Not pregnant Fertile patient must use effective contraception Able receive radiotherapy twice daily Vital function within ageappropriate normal range Audiological function less CTC grade 2 No medical contraindication radiotherapy chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Concurrent dexamethasone antiemetic allow , provide therapy fail Radiotherapy No concurrent cobalt irradiation Surgery See Disease Characteristics Other No prior treatment brain tumor malignancy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>untreated childhood medulloblastoma</keyword>
</DOC>